Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus

Fig. 2

Cumulative event rate of composite outcome of HHF and CV death (A), HHF (B), CV death (C), and an eGFR decline of > 50% during follow-up (D) for patients who received ARNI versus SGLT2i treatment in the IPTW-adjusted cohort. ARNI angiotensin receptor–neprilysin inhibitor, CV cardiovascular, eGFR estimated glomerular filtration rate, HHF hospitalization for heart failure, IPTW inverse probability treatment weighting, SGLT2i sodium–glucose cotransporter 2 inhibitors

Back to article page